| Symbol | AVLN |
|---|---|
| Name | AVALYN PHARMA INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 105 W FIRST ST., BOSTON, MA 02127 |
| Telephone | (206) 707-0340 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001540171 |
| Description | None |
(30% Negative) AVALYN PHARMA INC. (AVLN) Announces Delay in investigator Trials for lung function Due to Patient Enrollment Issues, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreAvalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Read more(10% Negative) AVALYN PHARMA INC. (AVLN) Announces Delay in programs Trials for Avalyn Due to Patient Enrollment Issues, Safety Review, Efficacy Assessment
Read moreAvalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Read moreNew Form SCHEDULE 13D - Avalyn Pharma Inc. <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0000899140-26-000428 <b>Size:</b> 108 KB
Read moreNew Form SCHEDULE 13D - Avalyn Pharma Inc. <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0001072613-26-000386 <b>Size:</b> 149 KB
Read moreNew Form SCHEDULE 13G - Avalyn Pharma Inc. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001193125-26-212017 <b>Size:</b> 23 KB
Read moreNovo Holdings A/S 🟡 adjusted position in 555.6K shares (5 derivative) of Avalyn Pharma Inc. (AVLN) at $18.00 ($10.0M) Transaction Date: May 01, 2026 | Filing ID: 000021
Read moreAvalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
Read more